Spanish competition authority CNMC has started sanction procedures against the Ireland-based Aspen Group pharmaceutical, as well as its Spanish distributor, Deco Pharma SL, over alleged abuses of market power, including denial of supply of certain drugs, excessive prices, and agreements to limit distribution and cause deliberate shortages.
The actions mentioned would be in violation of the country’s Competition Defense Law, as well as the Treaty on the Function of the European Union, by causing deliberate shortages of certain products in the national market in order to avoid the price guidelines set by the Spanish market, importing said products from other countries and allowing Aspen to set its own prices.
The CNMC’s probe was kick-started after information on these possible uncompetitive practices were notified by the Italian Competition Authority, from where some of the medications involved have been imported.
Full Content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Russia Imposes Fines on Google and TikTok for Non-Compliance
Jul 31, 2024 by
CPI
Senate Committee Blocks Attempt to Prevent AI Disclosure in Political Ads
Jul 31, 2024 by
CPI
UFC’s $335 Million Settlement with Fighters Rejected by Federal Judge
Jul 31, 2024 by
CPI
Alaska Air Extends Review for $1.9 Billion Hawaiian Airlines Deal Amid Antitrust Concerns
Jul 31, 2024 by
CPI
Pennsylvania Governor Opposes Nippon Steel’s Bid for U.S. Steel, Citing Union Concerns
Jul 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI